The DOI matches its Crossref record; 181 of the 184 references it cites were found in a registry or an index.
Opportunities and Challenges in the Delivery of mRNA-Based Vaccines
Open accessAbstract
In the past few years, there has been increasing focus on the use of messenger RNA (mRNA) as a new therapeutic modality. Current clinical efforts encompassing mRNA-based drugs are directed toward infectious disease vaccines, cancer immunotherapies, therapeutic protein replacement therapies, and treatment of genetic diseases. However, challenges that impede the successful translation of these molecules into drugs are that (i) mRNA is a very large molecule, (ii) it is intrinsically unstable and prone to degradation by nucleases, and (iii) it activates the immune system. Although some of these challenges have been partially solved by means of chemical modification of the mRNA, intracellular delivery of mRNA still represents a major hurdle. The clinical translation of mRNA-based therapeutics requires delivery technologies that can ensure stabilization of mRNA under physiological conditions. Here, we (i) review opportunities and challenges in the delivery of mRNA-based therapeutics with a focus on non-viral delivery systems, (ii) present the clinical status of mRNA vaccines, and (iii) highlight perspectives on the future of this promising new type of medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At present, the 3′ UTR is mainly derived from hemoglobin subunit α (HBA) and subunit β (HBB) genes,140 but it can also be derived from albumin (ALB), heat-shock protein 70 (Hsp70), tyrosine hydroxylase (TH), and collagen alpha 1 (COL1A1) genes.141–143”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [140]
In the citing paper
“Further, the 5′ cap protects the mRNA sterically from degradation by exonucleases, and it works synergistically with the poly(A) tail at the 3′ end, poly(A) binding proteins and translation initiation factor proteins to circularize mRNA and recruit ribosomes for initiating translation10,11.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [10]
In the citing paper
“As in mammals, the first or second nucleotide from the 5′ end is methylated on the 2′ hydroxyl of the ribose (2′-O-methylation), which prevents recognition by cytosolic sensors of viral RNA10, and hence prevents unintended immune responses.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [10]
In the citing paper
“The 5′ and 3′ UTRs flanking the coding region regulate mRNA translation, half-life and subcellular localization10,14.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173 · cited 2×
“The development of mRNA‐based drugs dates back to 1990 with the successful expression of a number of different proteins upon injecting mRNA encoding these proteins directly into the muscles of mice [24].”
BackgroundLiposome: classification, preparation, and applications
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati‐Koshki, K. (2013) · Nanoscale Research Letters · doi:10.1186/1556-276x-8-102 · Cited by 3,648
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature reviews. Immunology · doi:10.1038/nri1604 · Cited by 3,631
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Toxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286
The alphaviruses: gene expression, replication, and evolution.
Strauss, J. H., & Strauss, E. G. (1994) · Microbiological Reviews · doi:10.1128/mmbr.58.3.491-562.1994 · Cited by 2,221
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Flagged first, then by citations
3 of the 184 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Shin, D., Azizian, K.T., Henderson, J.M., Lebedev, A., Hogrefe, R.I., Houston, M., McCaffrey, A.P., and BioTechnologies, T. (2018). Exploring the Messenger RNA Capping Code: CleanCap Co-Transcriptional Capping Allows Synthesis of Cap 0, Cap 1, Cap 2 and (M6) A (M) Capped RNAs, Cell Press.
- Sahin, U., Karikó, K., and Türeci, Ö. (2014). mRNA-based therapeutics — developing a new class of drugs. Nat. Pub. Gr. · DOI · Paper page
Cited by
Sorted by citations
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555
The clinical progress of mRNA vaccines and immunotherapies
Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., & Anderson, D. G. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01294-2 · Cited by 823
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 852
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
Endosomal escape: A bottleneck for LNP-mediated therapeutics
Chatterjee, S., Kon, E., Sharma, P., & Peer, D. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307800120 · Cited by 628
Lipid nanoparticles for nucleic acid delivery: Current perspectives
Samaridou, E., Heyes, J. A., & Lutwyche, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.002 · Cited by 609
Nanomaterial Delivery Systems for mRNA Vaccines
Buschmann, M. D., Carrasco, M. J., Alishetty, S., Paige, M., Alameh, M. G., & Weissman, D. (2021) · Vaccines · doi:10.3390/vaccines9010065 · Cited by 582
Self-amplifying RNA vaccines for infectious diseases
Bloom, K., van den Berg, F., & Arbuthnot, P. (2021) · Gene Therapy · doi:10.1038/s41434-020-00204-y · Cited by 487
Sebastiani, F., Yanez Arteta, M., Lerche, M., Porcar, L., Lang, C., Bragg, R. A., Elmore, C. S., Krishnamurthy, V. R., Russell, R. A., Darwish, T., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c10064 · Cited by 409
Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines
Uddin, M. N., & Roni, M. A. (2021) · Vaccines · doi:10.3390/vaccines9091033 · Cited by 371
mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection
Xu, S., Yang, K., Li, R., & Zhang, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186582 · Cited by 368
Nanotechnology in healthcare, and its safety and environmental risks
Ma, X., Tian, Y., Yang, R., Wang, H., Allahou, L. W., Chang, J., Williams, G. R., Knowles, J. C., & Poma, A. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02901-x · Cited by 393
mRNA vaccines for COVID-19: what, why and how
Park, J. W., Lagniton, P. N. P., Liu, Y., & Xu, R.-H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59233 · Cited by 321
Recent advances in exosome-mediated nucleic acid delivery for cancer therapy
Zhang, Y., Liu, Q., Zhang, X., Huang, H., Tang, S., Chai, Y., Xu, Z., Li, M., Chen, X., Liu, J., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01472-z · Cited by 306
The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA
Patel, P., Ibrahim, N. M., & Cheng, K. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.03.002 · Cited by 298
Role of nanotechnology behind the success of mRNA vaccines for COVID-19
Khurana, A., Allawadhi, P., Khurana, I., Allwadhi, S., Weiskirchen, R., Banothu, A. K., Chhabra, D., Joshi, K., & Bharani, K. K. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101142 · Cited by 296
The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines
Morais, P., Adachi, H., & Yu, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.789427 · Cited by 281
Lipid Nanoparticle–mRNA Formulations for Therapeutic Applications
Wang, C., Zhang, Y., & Dong, Y. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00550 · Cited by 276
From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases
Pilkington, E. H., Suys, E. J. A., Trevaskis, N. L., Wheatley, A. K., Zukancic, D., Algarni, A., Al-Wassiti, H. A., Davis, T. P., Pouton, C. W., Kent, S. J., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.023 · Cited by 271
Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy
Guevara, M. L., Persano, F., & Persano, S. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.589959 · Cited by 261
mRNA vaccines in disease prevention and treatment
Zhang, G., Tang, T., Chen, Y., Huang, X., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01579-1 · Cited by 273
Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines
Aldosari, B. N., Alfagih, I. M., & Almurshedi, A. S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020206 · Cited by 248
Jeong, M., Lee, Y., Park, J., Jung, H., & Lee, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114990 · Cited by 232
Vaccine delivery systems toward lymph nodes
Ding, Y., Li, Z., Jaklenec, A., & Hu, Q. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113914 · Cited by 191
Exosomes as bio-inspired nanocarriers for RNA delivery: preparation and applications
Amiri, A., Bagherifar, R., Ansari Dezfouli, E., Kiaie, S. H., Jafari, R., & Ramezani, R. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03325-7 · Cited by 186
Souto, E. B., Blanco-Llamero, C., Krambeck, K., Kiran, N. S., Yashaswini, C., Postwala, H. I., Severino, P. B., Priefer, R., Prajapati, B. G., & Maheshwari, R. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.04.010 · Cited by 184
Recent Advances in Lipid Nanoparticles for Delivery of mRNA
Yang, L., Gong, L., Wang, P., Zhao, X., Zhao, F. H., Zhang, Z., Li, Y., & Huang, W. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122682 · Cited by 190
Recent Advancement in mRNA Vaccine Development and Applications
Fayez, N. A., Nassar, M. S., Alshehri, A. A., Alnefaie, M. K., Almughem, F. A., Alshehri, B. Y., Alawad, A. O., & Tawfik, E. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071972 · Cited by 187
Factors Affecting Stability of RNA – Temperature, Length, Concentration, pH, and Buffering Species
Chheda, U., Pradeepan, S., Esposito, E. A., Strezsak, S. R., Fernandez‐Delgado, O., & Kranz, J. K. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.11.023 · Cited by 177
Qin, F., Xia, F., Chen, H., Cui, B., Feng, Y., Zhang, P., Chen, J., & Luo, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.633776 · Cited by 167
Comparison of DLin-MC3-DMA and ALC-0315 for siRNA Delivery to Hepatocytes and Hepatic Stellate Cells
Ferraresso, F., Strilchuk, A. W., Juang, L. J., Poole, L. G., Luyendyk, J. P., & Kastrup, C. J. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00033 · Cited by 155
Therapeutic induction of antigen-specific immune tolerance
Kenison, J. E., Stevens, N. A., & Quintana, F. J. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00970-x · Cited by 162
Muskan, M., Abeysinghe, P., Cecchin, R., Branscome, H., Morris, K. V., & Kashanchi, F. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.02.025 · Cited by 158
Non-viral delivery of the CRISPR/Cas system: DNA versus RNA versus RNP
Lin, Y., Wagner, E., & Lächelt, U. (2022) · Biomaterials Science · doi:10.1039/d1bm01658j · Cited by 148
Nanomedicine-Based Approaches for mRNA Delivery
Uchida, S., Perche, F., Pichon, C., & Cabral, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00618 · Cited by 139
Zhang, H., Vandesompele, J., Braeckmans, K., Smedt, S. C. D., & Remaut, K. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00194f · Cited by 146
Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines
Rijkers, G. T., Weterings, N., Obregón‐Henao, A., Dutt, T., Dutt, T. S., van Overveld, F. J., & Henao-Tamayo, M. I. (2021) · Vaccines · doi:10.3390/vaccines9080848 · Cited by 139
Game changers in science and technology - now and beyond
Betz, U. A. K., Arora, L., Assal, R. A., de Azevedo, H. F. Z., Baldwin, J., Becker, M. S., Bostock, S., Cheng, V. W. T., Egle, T., Ferrari, N., et al. (2023) · Technological Forecasting and Social Change · doi:10.1016/j.techfore.2023.122588 · Cited by 153
Nanoplatforms for mRNA Therapeutics
Meng, C., Chen, Z., Li, G., Welte, T., & Shen, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000099 · Cited by 130
Circular RNA: A promising new star of vaccine
Xie, J., Ye, F., Deng, X., Tang, Y., Liang, J., Huang, X., Sun, Y., Tang, H., Lei, J., Zheng, S., et al. (2023) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2023-0122 · Cited by 129
Liposome-polymer complex for drug delivery system and vaccine stabilization
Sriwidodo, S., Umar, A. K., Wathoni, N., Zothantluanga, J. H., Das, S., & Luckanagul, J. A. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e08934 · Cited by 128
A perspective on oligonucleotide therapy: Approaches to patient customization
Thakur, S., Sinhari, A., Jain, P., & Jadhav, H. R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1006304 · Cited by 114
From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape
Chakraborty, C., Sharma, A. R., Bhattacharya, M., & Lee, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679344 · Cited by 114
Advances in mRNA non-viral delivery approaches
Ibba, M. L., Ciccone, G., Esposito, C. L., Catuogno, S., & Giangrande, P. H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113930 · Cited by 107
An overview of rational design of mRNA-based therapeutics and vaccines
To, K. K. W., & Cho, W. C. S. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1935859 · Cited by 110
Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions
Abulsoud, A. I., El‐Husseiny, H. M., El-Husseiny, A. A., El‐Mahdy, H. A., Ismail, A., Elkhawaga, S. Y., Khidr, E. G., Fathi, D., Mady, E. A., Najda, A., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113977 · Cited by 112
mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients
Bidram, M., Zhao, Y., Shebardina, N. G., Baldin, A. V., Bazhin, A. V., Ganjalikhany, M. R., Zamyatnin, A. A., & Ganjalıkhani-Hakemi, M. (2021) · Vaccines · doi:10.3390/vaccines9101060 · Cited by 111
The Progress and Promise of RNA Medicine─An Arsenal of Targeted Treatments
Sasso, J. M., Ambrose, B. J. B., Tenchov, R., Datta, R. S., Basel, M. T., DeLong, R. K., & Zhou, Q. A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00024 · Cited by 108
Engineering synthetic RNA devices for cell control
Dykstra, P. B., Kaplan, M., & Smolke, C. D. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00436-7 · Cited by 119
Sung, J. J., Alghoul, Z., Long, D., Yang, C., & Merlin, D. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121707 · Cited by 103
Wu, Z., & Li, T. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03015-x · Cited by 103
Review of structural design guiding the development of lipid nanoparticles for nucleic acid delivery
Cárdenas, M., Campbell, R. A., Arteta, M. Y., Lawrence, M. J., & Sebastiani, F. (2023) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2023.101705 · Cited by 108
Advances in gene-based vaccine platforms to address the COVID-19 pandemic
Pushparajah, D., Jimenez, S., Wong, S. L., Alattas, H., Nafissi, N., & Slavcev, R. A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.003 · Cited by 99
New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates
Ura, T., Yamashita, A., Mizuki, N., Okuda, K., & Shimada, M. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.11.054 · Cited by 97
RNA therapeutics in the clinic
Curreri, A. M., Sankholkar, D., Mitragotri, S., & Zhao, Z. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10374 · Cited by 100
Gene therapy to enhance angiogenesis in chronic wounds
Shaabani, E., Sharifiaghdam, M., Majidi, R. F., Smedt, S. C. D., Braeckmans, K., & Fraire, J. C. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.08.020 · Cited by 101
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials
Sobhani, N., Scaggiante, B., Morris, R. M., Chai, D., Catalano, M., Tardiel-Cyril, D. R., Neeli, P. K., Roviello, G., Mondani, G., & Li, Y. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102429 · Cited by 102
Zhang, C., Ma, Y., Zhang, J., Kuo, J. C., Zhang, Z., Xie, H., Zhu, J., & Liu, T. (2022) · Molecules · doi:10.3390/molecules27061943 · Cited by 95
New Advances in Biomedical Application of Polymeric Micelles
Figueiras, A., Domingues, C., Jarak, I., Santos, A. I., Parra, A., Pais, A. A. C. C., Alvarez‐Lorenzo, C., Concheiro, Á., Kabanov, A. V., Cabral, H., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081700 · Cited by 98
A predictive mechanistic model of drug release from surface eroding polymeric nanoparticles
Stiepel, R. T., Pena, E. S., Ehrenzeller, S. A., Gallovic, M. D., Lifshits, L. M., Genito, C. J., Bachelder, E. M., & Ainslie, K. M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.067 · Cited by 103
Gómez, X., Sanon, S., Zambrano, K., Asquel, S., Bassantes, M., Morales, J. E., Otáñez, G., Pomaquero, C., Villarroel, S., Zurita, A., et al. (2021) · npj Microgravity · doi:10.1038/s41526-021-00162-8 · Cited by 92
Nucleic Acid Vaccines for COVID-19: A Paradigm Shift in the Vaccine Development Arena
Chavda, V. P., Hossain, M. M. M., Beladiya, J., & Apostolopoulos, V. (2021) · Biologics · doi:10.3390/biologics1030020 · Cited by 92
Pesticide pestilence: Global scenario and recent advances in detection and degradation methods
Raj, A., Dubey, A., Malla, M. A., & Kumar, A. (2023) · Journal of Environmental Management · doi:10.1016/j.jenvman.2023.117680 · Cited by 96
Synthetic modified messenger RNA for therapeutic applications
Gao, M., Zhang, Q., Feng, X.-H., & Liu, J. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.020 · Cited by 89
Rational design and combinatorial chemistry of ionizable lipids for RNA delivery
Xu, Y., Golubovic, A., Xu, S., Pan, A., & Li, B. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb00649b · Cited by 87
A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues
Khandker, S. S., Godman, B., Jawad, M. I., Meghla, B. A., Tisha, T. A., Khondoker, M. U., Haq, M. A., Charan, J., Talukder, A. A., Azmuda, N., et al. (2021) · Vaccines · doi:10.3390/vaccines9121387 · Cited by 88
Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery
Mollé, L. M., Smyth, C. H., Yuen, D., & Johnston, A. P. R. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1809 · Cited by 95
Luo, M., Lee, L. K. C., Peng, B., Choi, C. H. J., Tong, W. Y., & Voelcker, N. H. (2022) · Advanced Science · doi:10.1002/advs.202201740 · Cited by 85
mRNA-Based Vaccines and Therapeutics for COVID-19 and Future Pandemics
Chavda, V. P., Soni, S., Vora, L. K., Soni, S., Khadela, A. D., & Ajabiya, J. (2022) · Vaccines · doi:10.3390/vaccines10122150 · Cited by 89
Zukancic, D., Suys, E. J. A., Pilkington, E. H., Algarni, A., Al-Wassiti, H. A., & Truong, N. P. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111068 · Cited by 81
Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines
Alfagih, I. M., Aldosari, B. N., AlQuadeib, B. T., Almurshedi, A. S., & Alfagih, M. M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010045 · Cited by 80
An overview on inactivated and live‐attenuated SARS‐CoV‐2 vaccines
Khoshnood, S., Arshadi, M., Akrami, S., Koupaei, M., Ghahramanpour, H., Shariati, A., Sadeghifard, N., & Heidary, M. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24418 · Cited by 76
Recent Advances in Cancer Vaccines: Challenges, Achievements, and Futuristic Prospects
Gupta, M., Wahi, A., Sharma, P., Nagpal, R., Raina, N., Kaurav, M., Bhattacharya, J., Oliveira, S. M. R., Dolma, K. G., Paul, A. K., et al. (2022) · Vaccines · doi:10.3390/vaccines10122011 · Cited by 80
van de Berg, D., Kis, Z., Behmer, C. F., Samnuan, K., Blakney, A. K., Kontoravdi, C., Shattock, R. J., & Shah, N. (2021) · npj Vaccines · doi:10.1038/s41541-021-00322-7 · Cited by 77
Self-Amplifying RNA Approach for Protein Replacement Therapy
Papukashvili, D., Rcheulishvili, N., Liu, C., Ji, Y., He, Y., & Wang, P. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112884 · Cited by 76
Microneedle-Based Vaccine Delivery: Review of an Emerging Technology
Mansoor, I., Eassa, H. A., Mohammed, K. H. A., El-Fattah, M. A. A., Abdo, M. H., Rashad, E., Eassa, H. A., Saleh, A., Amin, O. M., Nounou, M. I., et al. (2022) · AAPS PharmSciTech · doi:10.1208/s12249-022-02250-8 · Cited by 74
Current Status of COVID‐19 (Pre)Clinical Vaccine Development
Ye, T., Zhong, Z., García‐Sastre, A., Schotsaert, M., & Geest, B. G. D. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202008319 · Cited by 73
Gene Editing by Extracellular Vesicles
Kostyushev, D. S., Kostyusheva, A., Brezgin, S., Vv, S., Volchkova, E. V., Lukashev, A. N., & Chulanov, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197362 · Cited by 75
Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections
Asr, M. H., Dayani, F., Segherloo, F. S., Kamedi, A., Neill, A. O., MacLoughlin, R. J., & Doroudian, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041127 · Cited by 73
mRNA – A game changer in regenerative medicine, cell-based therapy and reprogramming strategies
Chabanovska, O., Galow, A.-M., David, R., & Lemcke, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114002 · Cited by 81
Nanomaterials for mRNA ‐based therapeutics: Challenges and opportunities
Li, D., Liu, Q., Yang, M., Xu, H., Zhu, M., Zhang, Y., Xu, J., Tian, C., Yao, J., Wang, L., et al. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10492 · Cited by 74
Mildner, R., Hak, S., Parot, J., Hyldbakk, A., Borgos, S. E., Some, D., Johann, C., & Caputo, F. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.03.004 · Cited by 74
mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles
Ouranidis, A., Vavilis, T., Mandala, E., Davidopoulou, C., Stamoula, Ε., Markopoulou, C. K., Karagianni, A., & Kachrimanis, K. (2021) · Biomedicines · doi:10.3390/biomedicines10010050 · Cited by 75
Zhang, Z., Shen, Q., & Chang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.843928 · Cited by 69
The Delivery of mRNA Vaccines for Therapeutics
Nitika, Wei, J., & Hui, A. (2022) · Life · doi:10.3390/life12081254 · Cited by 71
Siddiqui, S. A., Bahmid, N. A., Taha, A., Abdel‐Moneim, A. E., Shehata, A. M., Tan, C., Kharazmi, M. S., Li, Y., Assadpour, E., Castro‐Muñoz, R., et al. (2022) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2022.102772 · Cited by 68
Optimization of DOTAP/chol Cationic Lipid Nanoparticles for mRNA, pDNA, and Oligonucleotide Delivery
Sun, M., Dang, U. J., Yuan, Y., Psaras, A. M., Osipitan, O. O., Brooks, T. A., Lu, F., & Pasqua, A. J. D. (2022) · AAPS PharmSciTech · doi:10.1208/s12249-022-02294-w · Cited by 66
Functions of Circular RNA in Human Diseases and Illnesses
Gu, A., Jaijyan, D. K., Yang, S., Zeng, M., Pei, S., & Zhu, H. (2023) · Non-Coding RNA · doi:10.3390/ncrna9040038 · Cited by 65
Zhou, J., Ye, T., Yang, Y., Li, E., Zhang, K., Wang, Y., Chen, S., Hu, J., Zhang, K., Liu, F., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.028 · Cited by 68
Delivery of mRNA for regulating functions of immune cells
Shi, J. Y., Huang, M., Lu, Z.-D., Du, X., Shen, S., Xu, C., & Wang, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.033 · Cited by 62
Marques, R., Lacerda, R., & Romão, L. (2022) · Biomedicines · doi:10.3390/biomedicines10081865 · Cited by 71
Neoantigen Vaccines; Clinical Trials, Classes, Indications, Adjuvants and Combinatorial Treatments
Niemi, J. V. L., Sokolov, A. V., & Schiöth, H. B. (2022) · Cancers · doi:10.3390/cancers14205163 · Cited by 66
Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA
Miao, H., Huang, K., Li, Y., Li, R., Zhou, X., Shi, J., Tong, Z., Sun, Z., & Yu, A. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123050 · Cited by 66
Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy
Yoo, Y. J., Lee, C. H., Park, S. H., & Lim, Y. T. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.047 · Cited by 62
The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses
Föhse, K., Geckin, B., Zoodsma, M., Kılıç, G., Liu, Z., Röring, R. J., Overheul, G. J., van de Maat, J., Bulut, O. P., Hoogerwerf, J. J., et al. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109762 · Cited by 64
Recent Advances in the Noninvasive Delivery of mRNA
Qin, M., Du, G., & Sun, X. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00493 · Cited by 62
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines
Wei, J., & Hui, A.-M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102405 · Cited by 57
Principles of lipid nanoparticle design for mRNA delivery
Zhang, Y., Zhang, X., Gao, Y., & Liu, S. (2024) · BMEMat · doi:10.1002/bmm2.12116 · Cited by 62
mRNA, a Revolution in Biomedicine
Baptista, B., Carapito, R., Laroui, N., Pichon, C., & de Sousa, F. P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122090 · Cited by 61
Advances of mRNA vaccine in tumor: a maze of opportunities and challenges
Yuan, Y., Gao, F., Chang, Y., Zhao, Q., & He, X. (2023) · Biomarker Research · doi:10.1186/s40364-023-00449-w · Cited by 60
Metadata
- Authors
- Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., & Thakur, A.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Thakur, Aneesh
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2020-01-28
- Volume
- 12
- Issue
- 2
- Pages
- 102
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC7076378
- OpenAlex
- W3004416358
- Cited by
- 584
- References
- 184
- Citations by year
- 2026: 55 · 2025: 110 · 2024: 90 · 2023: 109 · 2022: 125 · 2021: 76 · 2020: 19
- FWCI
- 7.87
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Det Frie Forskningsråd (9041-00198B)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- mRNA vaccines, mRNA delivery, mRNA stability, nucleic acid degradation, immune activation, clinical translation, cancer immunotherapy, genetic disease treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
